Oncotarget

Researchers from Devi Ahilya Vishwavidyalaya, Indore discuss the challenges and shortcomings in drug discovery in academia, including the time-consuming nature, lack of synergy between academia and industry, and reasons for therapeutic molecule failures.

Researchers discuss the role of BCAS1 in diffuse gliomas and its potential as a diagnostic and therapeutic target. The study reveals the heterogeneous cell population in different tumor samples, showcasing the unique features of BCAS1+ cells through immunostaining and electron microscopy.

In this podcast, researchers Mark Lee and Luc GT Morris discuss genetic alterations in thyroid cancer that mediate resistance to BRAF inhibition and anaplastic transformation. They explore the limited response to standard therapy in advanced-stage thyroid cancers. They also talk about the potential efficacy of dual-target therapies and the combination of targeted therapy with immunotherapy.

Explore a new study on the effectiveness of a drug called Gardecer'dib in overcoming treatment resistance in glioblastoma, reducing cancer cell viability and enhancing cell death. Discover the potential immunomodulatory response and the upregulation of innate immune pathways with ATR inhibition.

This podcast discusses the effectiveness of osimertinib for patients with non-small cell lung cancer (NSCLC) and leptomeningeal disease. It presents a case report of a patient with NSCLC and activating EGFR mutations who showed a positive response to osimertinib treatment.

BUFFALO, NY- January 22, 2024 – On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center #published a new brief #report in Oncoscience (Volume 11), entitled, “My battle with cancer. Part 1.” “In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I must accomplish a mission. If everything happens for a reason, my cancer, in particular, I must find out how metastatic cancer can be treated with curative intent. This is my mission now, and the reason I was ever born. In January 2023, I understood the meaning of life, of my life. I was born to write this article. In this article, I argue that monotherapy with targeted drugs, even when used in sequence, cannot cure metastatic cancer. However, preemptive combinations of targeted drugs may, in theory, cure incurable cancer. Also, I share insights on various topics, including rapamycin, an anti-aging drug that can delay but not prevent cancer, through my personal journey.” DOI - https://doi.org/10.18632/oncoscience.593 Corresponding author - Mikhail V. Blagosklonny - Blagosklonny@oncotarget.com, Blagosklonny@rapalogs.com Sign up for free Altmetric alerts about this article - https://oncoscience.altmetric.com/details/email_updates?id=10.18632%2Foncoscience.593 Subscribe for free publication alerts from Oncoscience - https://www.oncoscience.us/subscribe/ Keywords - cancer, lung cancer, brain metastases, capmatinib, resistance, MET About Oncoscience Oncoscience is a traditional, peer-reviewed, bio-medical oncology research journal with FREE publication for authors and open-access for readers. To learn more about Oncoscience, please visit https://www.oncoscience.us/ and connect with us: Facebook - https://www.facebook.com/Oncoscience X - https://twitter.com/OncoscienceJrnl Instagram - https://www.instagram.com/oncosciencejrnl/ YouTube - https://www.youtube.com/@OncoscienceJournal LinkedIn - https://www.linkedin.com/company/oncoscience/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Researchers discuss how changes in bone marrow adipose tissue can serve as an early sign of progression from MGUS to multiple myeloma, providing opportunities for timely interventions and personalized treatment strategies.

Discover the exciting research exploring ATR inhibition using Guardisertib in patient-derived Glioblastoma cell lines. Learn about the synergistic effects with Temozolamide and Radiation Therapy, and the upregulation of innate immune-related pathways.

Researcher guests Alessia Roma, Lawrence D. Goodridge, and Paul A. Spagnuolo from the University of Guelph discuss the aggressive nature of acute myeloid leukemia (AML) and the potential of reductive carboxylation of glutamine as a target for novel therapies to improve patient outcomes. They highlight the importance of understanding metabolic vulnerabilities in AML and the advancements in targeting these vulnerabilities in drug development.

Exploring the relationship between oxidative metabolism and Mitochondrial Biogenesis in cancer metastasis, with a focus on the role of osteopontin splice variants. Impact of osteopontin A and C on Mitochondrial Biogenesis in breast tumor cells. Study on the role of osteopontin splice variants in regulating Mitochondrial Biogenesis in metastatic cancer cells.